Antibody Drug Conjugates And Bioconjugates
PUBLICATIONS ON SMARTAG® TECHNOLOGY
Drake PM et al. CAT-02-106, a site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models. Mol Cancer Ther. 2018,17: 161-168.
Albers A et al. A Stable, versatile conjugation chemistries for modifying aldehyde-containing biomolecules. Chemical Ligation: Tools for Biomolecule Synthesis and Modification. Ed. D’ Andrea, Romanelli A. 2017.
Kudirka R, Rabuka D. The Hydrazino-iso-Pictet-Spengler Ligation: a Versatile, Mild, and Efficient Aldehyde Conjugation Strategy to Generate Site-Specific, Positionally Programmable Antibody-Drug Conjugates. American Pharmaceutical Review. 2015, June 11.
Drake PM and Rabuka D. An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr Opin Chem Biol. 2015, 28:174-80.
Drake PM et al., Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes. Bioconjugate Chem., 2014, 25:1331-41.